Related Experiment Videos
Clinical trials of combination therapies for HIV infection. Rationale for development of multidrug therapy
1Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Maryland.
Journal of Acquired Immune Deficiency Syndromes
|January 1, 1990
Abstract
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
Overview of the preclinical development of an antiretroviral drug, 2',3'-dideoxyinosine.
Reviews of infectious diseases·1990
Clinical drug development: an analysis of phase II trials, 1970-1985.
Cancer treatment reports·1987
Hexamethylmelamine: a critical review of an active drug.
Cancer treatment reviews·1986
Gallium nitrate: the second metal with clinical activity.
Cancer treatment reports·1986
Therapeutic response in phase I trials of antineoplastic agents.
Cancer treatment reports·1986
Seroprevalence of HIV-1 and syphilis antibodies in blood donors in Gonder, Ethiopia, 1989-1993.
Journal of acquired immune deficiency syndromes·1994
Trends in risk behavior and HIV seroprevalence in heterosexual injection drug users in San Francisco, 1986-1992.
Journal of acquired immune deficiency syndromes·1994
Incidence of HIV-1 infection among young men in Thailand.
Journal of acquired immune deficiency syndromes·1994
Resistance to HIV-1 infection. Multicenter AIDS Cohort Study.
Journal of acquired immune deficiency syndromes·1994
Health care delivery, zidovudine use, and survival of women and men with AIDS.
Journal of acquired immune deficiency syndromes·1994
Thrush and fever as measures of immunocompetence in HIV-1-infected men.
Journal of acquired immune deficiency syndromes·1994
New Drugs in Myelofibrosis: Incremental Progress in Symptom Management Without Disease Modification.
American journal of hematology·2026
Molecular tumor board in advanced sarcoma: treatment implementation and clinical outcomes in a real-world cohort.
Journal of cancer research and clinical oncology·2026